Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 18;11(92):20131057.
doi: 10.1098/rsif.2013.1057. Print 2014 Mar 6.

Constructing and characterizing a bioactive small molecule and microRNA association network for Alzheimer's disease

Affiliations

Constructing and characterizing a bioactive small molecule and microRNA association network for Alzheimer's disease

Fanlin Meng et al. J R Soc Interface. .

Abstract

Alzheimer's disease (AD) is an incurable neurodegenerative disorder. Much effort has been devoted to developing effective therapeutic agents. Recently, targeting microRNAs (miRNAs) with small molecules has become a novel therapy for human diseases. In this study, we present a systematic computational approach to construct a bioactive Small molecule and miRNA association Network in AD (SmiRN-AD), which is based on the gene expression signatures of bioactive small molecule perturbation and AD-related miRNA regulation. We also performed topological and functional analysis of the SmiRN-AD from multiple perspectives. At the significance level of p ≤ 0.01, 496 small molecule-miRNA associations, including 25 AD-related miRNAs and 275 small molecules, were recognized and used to construct the SmiRN-AD. The drugs that were connected with the same miRNA tended to share common drug targets (p = 1.72 × 10(-4)) and belong to the same therapeutic category (p = 4.22 × 10(-8)). The miRNAs that were linked to the same small molecule regulated more common miRNA targets (p = 6.07 × 10(-3)). Further analysis of the positive connections (quinostatin and miR-148b, amantadine and miR-15a) and the negative connections (melatonin and miR-30e-5p) indicated that our large-scale predictions afforded specific biological insights into AD pathogenesis and therapy. This study proposes a holistic strategy for deciphering the associations between small molecules and miRNAs in AD, which may be helpful for developing a novel effective miRNA-associated therapeutic strategy for AD. A comprehensive database for the SmiRN-AD and the differential expression patterns of the miRNA targets in AD is freely available at http://bioinfo.hrbmu.edu.cn/SmiRN-AD/.

Keywords: Alzheimer's disease; bioinformatics; drug; microRNA; small molecule; therapeutics.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Small molecules–miRNAs network in AD. Network organization of miRNA and small molecule associations. Triangles indicate miRNAs and circles signify small molecules. (Online version in colour.)
Figure 2.
Figure 2.
Degree distribution of small molecule and miRNA nodes. (a) Degree distribution of the small molecule nodes. (b) Degree distribution of miRNA nodes.
Figure 3.
Figure 3.
Distribution of ATC top-level classes among small molecules. Alimentary tract and metabolism (A), blood and blood-forming organs (B), cardiovascular system (C), dermatologicals (D), genito-urinary system and sex hormones (G), systemic hormonal preparations, excluding sex hormones and insulins (H), anti-infectives for systemic use (J), antineoplastic and immunomodulating agents (L), musculo-skeletal system (M), nervous system (N), antiparasitic products, insecticides and repellents (P), respiratory system (R), sensory organs (S) and various (V). (Online version in colour.)
Figure 4.
Figure 4.
MiR-148b in the mTOR signalling pathway. The mTOR signalling pathway from KEGG. (Online version in colour.)
Figure 5.
Figure 5.
MiR-15a in the AD pathway. The AD pathway from KEGG. (Online version in colour.)

Similar articles

Cited by

References

    1. Goedert M, Spillantini MG. 2006. A century of Alzheimer's disease. Science 314, 777–781. (10.1126/science.1132814) - DOI - PubMed
    1. Alzheimer's Association. 2012. Alzheimer's disease facts and figures. Alzheimers Dement. 8, 131–168. (10.1016/j.jalz.2012.02.001) - DOI - PubMed
    1. Scheuner D, et al. 1996. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864–870. (10.1038/nm0896-864) - DOI - PubMed
    1. De Strooper B, Iwatsubo T, Wolfe MS. 2012. Presenilins and gamma-secretase: structure, function, and role in Alzheimer Disease. Cold Spring Harb. Perspect. Med. 2, a006304 (10.1101/cshperspect.a006304) - DOI - PMC - PubMed
    1. Mattson MP. 2004. Pathways towards and away from Alzheimer's disease. Nature 430, 631–639. (10.1038/nature02621) - DOI - PMC - PubMed

Publication types

MeSH terms